Effect of Utipro® (containing gelatinxyloglucan) against Escherichia coli invasion of intestinal epithelial cells: Results of an in vitro study

Future Microbiology

Volumn 11, Issue 5, 2016, Pages 651-658

  De Servi, Barbara ^a   Ranzini, Francesco ^a   Piqué, Nuria ^b  

^a In Vitro Research Laboratories   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Gelatin; Intestinal epithelial cells; Urinary tract infection; Utipro ; Xyloglucan

Indexed keywords

ANTIBIOTIC AGENT; CYTOPROTECTIVE AGENT; GELATIN; HEMICELLULOSE; PLANT EXTRACT; UNCLASSIFIED DRUG; UTIPRO; GLUCAN; XYLAN; XYLOGLUCAN;

ARTICLE; BACTERIAL CELL; BACTERIAL COUNT; BACTERIUM ADHERENCE; CACO-2 CELL LINE; CELL INVASION; CELL INVASION ASSAY; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ESCHERICHIA COLI; GOBLET CELL; HIBISCUS SABDARIFFA; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA; NONHUMAN; PRIORITY JOURNAL; SPECIES INVASION; TAMARIND; TIGHT JUNCTION; TRANSEPITHELIAL RESISTANCE; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; ESCHERICHIA COLI INFECTIONS; INTESTINE; MICROBIOLOGY; PHYSIOLOGY;

BACTERIAL ADHESION; CACO-2 CELLS; EPITHELIAL CELLS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GELATIN; GLUCANS; HUMANS; INTESTINES; TIGHT JUNCTIONS; XYLANS;

EID: 85010302950     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb-2016-0022     Document Type: Article

References (28)

1. Magliano E, Grazioli V, Deflorio L et al. Gender and age-dependent etiology of community-acquired urinary tract infections. Sci. World J. 2012, 349597 (2012).
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. 113(Suppl. 1A), 5S-13S (2002).
3. Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA 312(16), 1677-1684 (2014).
4. Bermingham SL, Ashe JF. Systematic review of the impact of urinary tract infections on health-related quality of life. BJU Int. 110(11 Pt C), E830-E836 (2012).
5. Ernst EJ, Ernst ME, Hoehns JD, Bergus GR. Women's quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health Qual. Life Outcomes 3, 45 (2005).
6. Abrahamian FM, Krishnadasan A, Mower WR, Moran GJ, Coker JR, Talan DA. The association of antimicrobial resistance with cure and quality of life among women with acute uncomplicated cystitis. Infection 39(6), 507-514 (2011).
7. Ciani O, Grassi D, Tarricone R. An economic perspective on urinary tract infection: the "costs of resignation". Clin. Drug Investig. 33(4), 255-261 (2013).
8. Minardi D, d'Anzeo G, Cantoro D, Conti A, Muzzonigro G. Urinary tract infections in women: etiology and treatment options. Int. J. Gen. Med. 4, 333-343 (2011).
9. Zhang L, Foxman B, Marrs C. Both urinary and rectal Escherichia coli isolates are dominated by strains of phylogenetic group B2. J. Clin. Microbiol. 40(11), 3951-3955 (2002).
10. Moreno E, Andreu A, Pigrau C, Kuskowski MA, Johnson JR, Prats G. Relationship between Escherichia coli strains causing acute cystitis in women and the fecal E. coli population of the host. J. Clin. Microbiol. 46(8), 2529-2534 (2008).
11. Nielsen KL, Dynesen P, Larsen P, Frimodt-MØller N. Faecal Escherichia coli from patients with E. coli urinary tract infection and healthy controls who have never had a urinary tract infection. J. Med. Microbiol. 63(Pt 4), 582-589 (2014).
12. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N. Engl. J. Med. 366(11), 1028-1037 (2012).
13. Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad. Med. 122(6), 7-15 (2010).
14. Howell AB. Cranberry proanthocyanidins and the maintenance of urinary tract health. Crit. Rev. Food Sci. Nutr. 42(3 Suppl.), 273-278 (2002).
15. Howell AB, Botto H, Combescure C et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect. Dis. 10, 94 (2010).
16. Gupta A, Dwivedi M, Mahdi AA, Nagana Gowda GA, Khetrapal CL, Bhandari M. Inhibition of adherence of multi-drug resistant E. coli by proanthocyanidin. Urol. Res. 40(2), 143-150 (2012).
17. Chisholm AH. Probiotics in preventing recurrent urinary tract infections in women: a literature review. Urol. Nurs. 35(1), 18-21 (2015).
18. Gnessi L, Bacarea V, Marusteri M, Pique N. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial. BMC Gastroenterol. 15(1), 153 (2015).
19. Bueno L, Theodorou V, Sekkal S. Xyloglucan: a new agent to protect the intestinal mucosa and to prevent bacterially-mediated alteration of tight junction permeability [Abstract P1675]. UEG J. 2(1 Suppl.), A591 (2014).
20. Yamamoto S, Tsukamoto T, Terai A, Kurazono H, Takeda Y, Yoshida O. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. J. Urol. 157(3), 1127-1129 (1997).
21. Katouli M. Population structure of gut Escherichia coli and its role in development of extra-intestinal infections. Iran. J. Microbiol. 2(2), 59-72 (2010).
22. Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal Escherichia coli. Nat. Rev. Microbiol. 8(3), 207-217 (2010).
23. Frommel U, Lehmann W, Rodiger S et al. Adhesion of human and animal Escherichia coli strains in association with their virulenceassociated genes and phylogenetic origins. Appl. Environ. Microbiol. 79(19), 5814-5829 (2013).
24. Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, Langguth P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside-and outside-directed carrier-mediated transport. J. Pharm. Sci. 89(1), 63-75 (2000).
25. Pontier C, Pachot J, Botham R, Lenfant B, Arnaud P. HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer. J. Pharm. Sci. 90(10), 1608-1619 (2001).
26. Stewart WW. Functional connections between cells as revealed by dye-coupling with a highly fluorescent naphthalimide tracer. Cell 14(3), 741-759 (1978).
27. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 52(7), 988-997 (2003).
28. Alexea O, Bacarea V, Pique N. The combination of oligo-and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: results of a randomised, placebocontrolled, double-blind, parallel group, multicentre clinical trial. UEG J. doi:10.1177/2050640615615050 (2015) (Epub ahead of print).